214 related articles for article (PubMed ID: 23046710)
1. Relationship of CD44+CD24-/low breast cancer stem cells and axillary lymph node metastasis.
Wei W; Hu H; Tan H; Chow LW; Yip AY; Loo WT
J Transl Med; 2012 Sep; 10 Suppl 1(Suppl 1):S6. PubMed ID: 23046710
[TBL] [Abstract][Full Text] [Related]
2. Axillary Skip Metastases and the False-Negative Rate of Sentinel Lymph Node Biopsy in Patients With Breast Cancer Are Related to Negative ALDH-1 Expression and Ki-67 Expression.
Kim WG; Lee J
Int J Surg Pathol; 2017 Aug; 25(5):397-405. PubMed ID: 28145149
[TBL] [Abstract][Full Text] [Related]
3. Impact of CD44+CD24- cells on non-sentinel axillary lymph node metastases in sentinel node-positive breast cancer.
Nogi H; Suzuki M; Kamio M; Kato K; Kawase K; Toriumi Y; Takeyama H; Fukushima H; Morikawa T; Uchida K
Oncol Rep; 2011 Apr; 25(4):1109-15. PubMed ID: 21308353
[TBL] [Abstract][Full Text] [Related]
4. [Study on the correlation factors on CD44+ CD24-/low ESA+ Lin- cell ratio in breast cancer].
Wang R; Yang XQ; Lü Q
Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Jan; 45(1):53-6. PubMed ID: 24527582
[TBL] [Abstract][Full Text] [Related]
5. CD44+/CD24- cells and lymph node metastasis in stage I and II invasive ductal carcinoma of the breast.
Tiezzi DG; Valejo FA; Marana HR; Carrara HH; Benevides L; Antonio HM; Sicchieri RD; Milanezi CM; Silva JS; de Andrade JM
Med Oncol; 2012 Sep; 29(3):1479-85. PubMed ID: 21713550
[TBL] [Abstract][Full Text] [Related]
6. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.
Zhong Y; Shen S; Zhou Y; Mao F; Guan J; Lin Y; Xu Y; Sun Q
Med Oncol; 2014 Mar; 31(3):864. PubMed ID: 24519209
[TBL] [Abstract][Full Text] [Related]
7. Are CD44
Ryspayeva DE; Smolanka II; Dudnichenko АS; Lyashenko AA; Grinevich YA; Gurianov VG; Koshubarova MV; Seleznev AA
Exp Oncol; 2017 Sep; 39(3):224-228. PubMed ID: 28967636
[TBL] [Abstract][Full Text] [Related]
8. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis.
Li W; Ma H; Zhang J; Zhu L; Wang C; Yang Y
Sci Rep; 2017 Oct; 7(1):13856. PubMed ID: 29062075
[TBL] [Abstract][Full Text] [Related]
9. [Pilot study on the correlation between high incidence of CD44+/CD24 -/low/ABCG2- cells and poor prognosis in breast cancer].
Gong JF; Yuan YH; Song GH; Yu J; Han Y; Jia J; Ren J
Beijing Da Xue Xue Bao Yi Xue Ban; 2008 Oct; 40(5):465-70. PubMed ID: 18931706
[TBL] [Abstract][Full Text] [Related]
10. CD44/CD24 as potential prognostic markers in node-positive invasive ductal breast cancer patients treated with adjuvant chemotherapy.
Adamczyk A; Niemiec JA; Ambicka A; Mucha-Małecka A; Mituś J; Ryś J
J Mol Histol; 2014 Feb; 45(1):35-45. PubMed ID: 23835592
[TBL] [Abstract][Full Text] [Related]
11. A CD44⁻/CD24⁺ phenotype is a poor prognostic marker in early invasive breast cancer.
Ahmed MA; Aleskandarany MA; Rakha EA; Moustafa RZ; Benhasouna A; Nolan C; Green AR; Ilyas M; Ellis IO
Breast Cancer Res Treat; 2012 Jun; 133(3):979-95. PubMed ID: 22119938
[TBL] [Abstract][Full Text] [Related]
12. The role of CD44+/CD24-/low biomarker for screening, diagnosis and monitoring of breast cancer.
Camerlingo R; Ferraro GA; De Francesco F; Romano M; Nicoletti G; Di Bonito M; Rinaldo M; D'Andrea F; Pirozzi G
Oncol Rep; 2014 Mar; 31(3):1127-32. PubMed ID: 24366074
[TBL] [Abstract][Full Text] [Related]
13. Semi-quantitative evaluation of CD44(+) /CD24(-) tumor cell distribution in breast cancer tissue using a newly developed fluorescence immunohistochemical staining method.
Kai M; Onishi H; Souzaki M; Tanaka H; Kubo M; Tanaka M; Katano M
Cancer Sci; 2011 Dec; 102(12):2132-8. PubMed ID: 21838786
[TBL] [Abstract][Full Text] [Related]
14. In situ identification of CD44+/CD24- cancer cells in primary human breast carcinomas.
Perrone G; Gaeta LM; Zagami M; Nasorri F; Coppola R; Borzomati D; Bartolozzi F; Altomare V; Trodella L; Tonini G; Santini D; Cavani A; Muda AO
PLoS One; 2012; 7(9):e43110. PubMed ID: 23028444
[TBL] [Abstract][Full Text] [Related]
15. TGFβ1 Promotes Breast Cancer Local Invasion and Liver Metastasis by Increasing the CD44
Zhang C; Gao H; Li C; Tu J; Chen Z; Su W; Geng X; Chen X; Wang J; Pan W
Technol Cancer Res Treat; 2018 Jan; 17():1533033818764497. PubMed ID: 29658391
[TBL] [Abstract][Full Text] [Related]
16. CD44+/CD24- breast cancer cells isolated from MCF-7 cultures exhibit enhanced angiogenic properties.
Sun H; Jia J; Wang X; Ma B; Di L; Song G; Ren J
Clin Transl Oncol; 2013 Jan; 15(1):46-54. PubMed ID: 22855175
[TBL] [Abstract][Full Text] [Related]
17. CD44/CD24 expression in recurrent gastric cancer: a retrospective analysis.
Yong CS; Ou Yang CM; Chou YH; Liao CS; Lee CW; Lee CC
BMC Gastroenterol; 2012 Jul; 12():95. PubMed ID: 22839505
[TBL] [Abstract][Full Text] [Related]
18. Association of human breast cancer CD44
Qiao X; Zhang Y; Sun L; Ma Q; Yang J; Ai L; Xue J; Chen G; Zhang H; Ji C; Gu X; Lei H; Yang Y; Liu C
Elife; 2021 Jul; 10():. PubMed ID: 34318746
[TBL] [Abstract][Full Text] [Related]
19. Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.
Bane A; Viloria-Petit A; Pinnaduwage D; Mulligan AM; O'Malley FP; Andrulis IL
Breast Cancer Res Treat; 2013 Jul; 140(1):195-205. PubMed ID: 23813303
[TBL] [Abstract][Full Text] [Related]
20. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.
Cufi S; Corominas-Faja B; Vazquez-Martin A; Oliveras-Ferraros C; Dorca J; Bosch-Barrera J; Martin-Castillo B; Menendez JA
Oncotarget; 2012 Apr; 3(4):395-8. PubMed ID: 22565037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]